29 Erectile Dysfunction Clinical Trials in Grand Rapids, MI (2026)

Q: How do I join a clinical trial in Grand Rapids?

Browse available studies, click one that interests you, and complete the free eligibility form. A study coordinator at the Grand Rapids research site will contact you.

Recruiting Erectile Dysfunction Studies in Grand Rapids

NCT07070232Recruiting

A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors

This study will evaluate the safety, efficacy, optimal dose, and pharmacokinetics (PK) of BNT326 as monotherapy (Part 1) and as combination treatment with immunotherapeutic agents (Part 2) in particip...

Grand Rapids, MI980 participantsBioNTech SE

View Study Details

NCT05489211Recruiting

Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)

TROPION-PanTumor03 will investigate the safety, tolerability, and anti-tumour activity of Datopotamab Deruxtecan (Dato-DXd) as Monotherapy and in Combination with Anticancer Agents in Patients with Ad...

Grand Rapids, MI454 participantsAstraZeneca

View Study Details

NCT07197827Recruiting

A Study of YL242 in Subjects With Advanced Solid Tumors

This is a multicenter, open-label study to evaluate the safety and tolerability of YL242 monotherapy and combination in participants with advanced solid malignant tumors....

Grand Rapids, MI424 participantsMediLink Therapeutics (Suzhou) Co., Ltd.

View Study Details

NCT06253871Recruiting

A Phase 1/1b Study of IAM1363 in HER2 Cancers

This is a Phase 1/1b open-label, multi-center dose escalation and dose optimization study designed to evaluate the safety and preliminary efficacy of IAM1363 in participants with advanced cancers that...

Grand Rapids, MI383 participantsIambic Therapeutics, Inc

View Study Details

NCT06730750Recruiting

A Study of BMS-986490 With or Without Bevacizumab in Advanced Solid Tumors

This is a study of BMS-986490 as a monotherapy and in combination with bevacizumab in participants with select advanced solid tumors known to express CEACAM5....

Grand Rapids, MI360 participantsBristol-Myers Squibb

View Study Details

NCT07136779Recruiting

First-in-Human Trial of VBC101 in Participants With Advanced Solid Tumor Malignancies

This is a multicenter, open-label, multiple-dose, FIH Phase 1/2a trial. The Phase 1 portion adopts an accelerated titration for the first dose level, followed by BOIN design to identify the MTD and/or...

Grand Rapids, MI310 participantsVelaVigo Bio Inc

View Study Details

NCT04005378Recruiting

Disengagement in CSC: Identifying Those at Risk and Addressing Their Needs

Maintaining treatment engagement is critical for first episode psychosis patients to experience gains possible with coordinated specialty care (CSC). This study is designed to identify CSC participant...

Grand Rapids, MI300 participantsNorthwell Health

View Study Details

NCT07335497Recruiting

CR-001 in Adult Participants With Locally Advanced or Metastatic Solid Tumors

The purpose of this study is to determine the safety and tolerability of monotherapy CR-001 and identify the maximum tolerated dose (MTD), and/or optimal biologic dose and Recommended Phase 2 Dose(s) ...

Grand Rapids, MI290 participantsCrescent Biopharma, Inc.

View Study Details

NCT06840886Recruiting

A Study of PHST001 in Advanced Solid Tumors

This is a multi-center, first-in-human (FIH), open-label, Phase 1a/1b dose escalation and dose expansion study to assess the safety, PK, pharmacodynamics, and antitumor activity of PHST001 monotherapy...

Grand Rapids, MI272 participantsPheast Therapeutics

View Study Details

NCT06752681Recruiting

To Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of DAY301 in Participants With Locally Advanced or Metastatic Solid Tumors

This is a Phase 1a/1b, open-label, dose escalation and expansion study to evaluate the safety and anti-tumor activity of DAY301, a PTK7-directed antibody-drug conjugate in participants with advanced o...

Grand Rapids, MI254 participantsDay One Biopharmaceuticals, Inc.

View Study Details

NCT06242470Recruiting

A Study of MGC026 in Participants With Advanced Solid Tumors

The study is designed to understand the safety, tolerability, pharmacokinetics, immunogenicity, and preliminary antitumor activity of MGC026 in participants with relapsed or refractory, unresectable, ...

Grand Rapids, MI250 participantsMacroGenics

View Study Details

NCT06234397Recruiting

Dose Escalation and Expansion Study of BH3120 Alone or With Pembrolizuamb in Advanced or Metastatic Solid Tumors

This is a First-in-Human, Phase 1, Dose-Escalation and Dose-Expansion study of BH3120, as a single agent and in combination with pembrolizumab, to assess safety, tolerability, MTD, RP2D, PK, and effic...

Grand Rapids, MI245 participantsHanmi Pharmaceutical Company Limited

View Study Details

NCT06413680Recruiting

A First-In Human (FIH) Trial to Find Out if REGN10597 is Safe and How Well it Works for Adult Participants With Advanced Solid Organ Malignancies

This study is researching an experimental drug called REGN10597 (called "study drug"). The study is focused on patients with certain solid tumors that are in an advanced stage. The aim of the study i...

Grand Rapids, MI240 participantsRegeneron Pharmaceuticals

View Study Details

NCT05985655Recruiting

Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors

The primary purpose of this study is to assess the safety, tolerability, pharmacokinetics (PK) and anti-tumor activity of GTAEXS617-001 in participants with advanced solid tumors....

Grand Rapids, MI230 participantsExscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.

View Study Details

NCT07205718Recruiting

A Study of TAK-188 in Adults With Advanced or Spreading Solid Tumors

TAK-188 is a new medicine that targets a protein called CCR8, which is found on the surface of certain cells (Tregs) inside tumors. These cells can weaken the body's ability to fight cancer. TAK-188 m...

Grand Rapids, MI223 participantsTakeda

View Study Details

NCT06577987Recruiting

Safety/Efficacy Study of CID-078 in Patients With Advanced Solid Tumor Malignancies

This is a first-in-human, multicenter, open-label, phase 1 study to evaluate safety, tolerability, and efficacy of CID-078, a Cyclin A/B-RxL inhibitor, in patients with advanced solid tumors....

Grand Rapids, MI220 participantsCircle Pharma

View Study Details

NCT05902988Recruiting

A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer

This is a first-in-human phase I/II study to examine the safety, tolerability and preliminary efficacy of VLS-1488 in subjects with advanced cancers....

Grand Rapids, MI200 participantsVolastra Therapeutics, Inc.

View Study Details

NCT04046497Recruiting

Artificial Intelligence to Measure Adherence to Oral Medication

The aims of this project is to use an artificial intelligence (AI) smartphone app to provide support for medication adherence by patients with first episode psychosis....

Grand Rapids, MI200 participantsNorthwell Health

View Study Details

NCT07266428Recruiting

A Study of OTP-01, a Dual Paratopic PD-1/VEGFR2 Antibody, in Patients With Advanced Solid Tumors

The main goals of this clinical trial are to find out what the best dose of the study drug, OTP-01, is for patients with solid tumors through understanding how it is tolerated and any side effects tha...

Grand Rapids, MI170 participantsOttimo Pharma Limited

View Study Details

NCT07293754Recruiting

An Early Phase Trial of RPTR-1-201 in Advanced Solid Tumors

This is an early phase trial designed to evaluate the safety, tolerability, and preliminary antitumor activity of RPTR-1-201 in adults with advanced solid tumors. The trial includes dose escalation an...

Grand Rapids, MI150 participantsRepertoire Immune Medicines

View Study Details

NCT06270706Recruiting

A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors

This is a Phase 1a/1b, dose-escalation/expansion, consecutive-cohort, open-label study to evaluate the safety, tolerability, PK, PD, and preliminary evidence of antitumor activity of PLN-101095 in com...

Grand Rapids, MI124 participantsPliant Therapeutics, Inc.

View Study Details

NCT07213817Recruiting

A Study to Assess the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic, Immunogenicity and Antitumour Activity of IPN60300 in Adults With Locally Advanced or Metastatic Solid Tumours

This study aims to find the right dosage and evaluate the safety and effectiveness of the drug IPN60300 in adults with advanced solid tumours, which are cancers that have spread to other parts of the ...

Grand Rapids, MI114 participantsIpsen

View Study Details

NCT07361562Recruiting

A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors

This is an open-label, phase 1/1b study evaluating the safety, tolerability, pharmacokinetic (what the body does to the drug), pharmacodynamic (what the drug does to the body), and antitumor activity ...

Grand Rapids, MI100 participantsCogent Biosciences, Inc.

View Study Details

NCT06833008Recruiting

A Study to Assess a New Medicine Called IPN01195 When Administered Alone in Adults With Advanced Solid Tumours

The purpose of this study is to determine the appropriate dosage, safety and effectiveness of a new study drug IPN01195 in adults with advanced solid tumours. The participants in this study will have...

Grand Rapids, MI85 participantsIpsen

View Study Details

NCT06730347Recruiting

A Study of Lorigerlimab in Participants With Advanced Solid Tumors

Study CP-MGD019-03 is an open-label study of lorigerlimab in participants with platinum-resistant ovarian cancer (PROC) or clear cell gynecologic cancer (CCGC). Approximately 60 participants will be e...

Grand Rapids, MI80 participantsMacroGenics

View Study Details

NCT07115043Recruiting

A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors

A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors...

Grand Rapids, MI60 participantsAstraZeneca

View Study Details

NCT06750185Recruiting

Safety and Preliminary Effectiveness of BNT317, an Investigational Therapy for Advanced Solid Tumors

This is a first-in-human (FIH), open-label, multiple-site, dose escalation study which will evaluate the safety, tolerability, pharmacokinetics (PK), and immunogenicity of increasing doses of BNT317 i...

Grand Rapids, MI39 participantsBioNTech SE

View Study Details

NCT07584226Recruiting

A First-in-human Study of RLY-8161 in Advanced NRAS-Mutant Solid Tumors

This is a Phase 1 first-in-human, open-label multicenter study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of RLY-8161, a...

Grand Rapids, MI35 participantsRelay Therapeutics, Inc.

View Study Details

NCT06943521Recruiting

A Study of MT-4561 in Patients With Various Advanced Solid Tumors

This is a First In Human (FIH), multicenter, open-label, Phase I/II study to evaluate safety, tolerability, Pharmacokinetics (PK), pharmacodynamics, and efficacy of MT-4561 in patients with advanced s...

Grand Rapids, MI27 participantsMitsubishi Tanabe Pharma America Inc.

View Study Details

About Erectile Dysfunction Clinical Trials in Grand Rapids

Erectile dysfunction is the inability to achieve or maintain an erection sufficient for satisfactory sexual performance. It affects about 30 million men in the U.S. and is often a sign of underlying cardiovascular disease. Treatment includes PDE5 inhibitors, vacuum devices, and penile implants.

There are currently 29 erectile dysfunction clinical trials recruiting participants in Grand Rapids, MI. These studies are seeking a combined 6,819 participants. Research is being sponsored by BioNTech SE, AstraZeneca, MediLink Therapeutics (Suzhou) Co., Ltd. and 21 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Erectile Dysfunction Clinical Trials in Grand Rapids — FAQ

Are there erectile dysfunction clinical trials in Grand Rapids?

Yes, there are 29 erectile dysfunction clinical trials currently recruiting in Grand Rapids, MI. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Grand Rapids?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Grand Rapids research site will contact you about next steps.

Are clinical trials in Grand Rapids free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Grand Rapids studies also compensate for your time and travel.

What erectile dysfunction treatments are being tested?

The 29 active trials in Grand Rapids are testing new therapies including novel drugs, biologics, and treatment approaches for erectile dysfunction.

Data updated July 13, 2026 from ClinicalTrials.gov